Literature DB >> 19616183

Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit.

Kellie L Flood1, Maria B Carroll, Cyndi V Le, Cynthia J Brown.   

Abstract

BACKGROUND: A novel Oncology-Acute Care for Elders (OACE) unit that uses an interdisciplinary team to enhance recognition and management of geriatric syndromes in hospitalized older adult cancer patients has been established at Barnes-Jewish Hospital (St. Louis, Missouri). The OACE team includes a clinical pharmacist whose primary role is to improve the appropriateness of prescribing.
OBJECTIVE: Using polypharmacy as the prototypical geriatric syndrome addressed by the OACE team, the objective of this study was to document the processes of communication of an interdisciplinary team and the impact on polypharmacy when the treating physician did not participate in the daily interdisciplinary team rounds.
METHODS: This was a prospective, observational study of older cancer patients admitted to the OACE unit. We tracked processes and outcomes of interdisciplinary communication regarding medications by prospectively recording OACE team recommendations and evaluating the frequency of implementation of these recommendations through a chart review. Treating physicians, who did not attend team rounds, received these recommendations on a communication form placed in the patient's chart.
RESULTS: Forty-seven patients were included in the study. The mean (SD) age was 73.5 (7.5) years. Twenty-one percent (10/47) of patients were prescribed > or =1 Beers medication as part of their home-care regimen before admission to the OACE unit. The OACE team made 51 medication recommendations, and 42 of those recommendations (82%) were implemented. Twenty-five patients (53%) had an alteration in their medication regimen; 13 (28%) had a potentially inappropriate medication discontinued. A medication error was corrected in ~1 of every 8 patients (6/47 [13%]).
CONCLUSIONS: We found that polypharmacy was common in older cancer patients and increased during hospitali-zation. We also found that most OACE team recommendations communicated to physicians were implemented even though the primary physicians were not members of the OACE team. Future randomized trials are needed to assess the impact of the OACE team model of care on adverse events, survival, and cost in hospitalized older adult cancer patients.

Entities:  

Mesh:

Year:  2009        PMID: 19616183     DOI: 10.1016/j.amjopharm.2009.05.002

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  21 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

Review 2.  Polypharmacy in older adults with cancer.

Authors:  Ronald J Maggiore; Cary P Gross; Arti Hurria
Journal:  Oncologist       Date:  2010-04-24

Review 3.  Elderly acute myeloid leukemia: assessing risk.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 4.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 5.  Cardiovascular complications of breast cancer therapy in older adults.

Authors:  Chetan Shenoy; Igor Klem; Anna Lisa Crowley; Manesh R Patel; Mark A Winchester; Cynthia Owusu; Gretchen G Kimmick
Journal:  Oncologist       Date:  2011-07-07

6.  The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Authors:  Kathleen Elliot; Janet A Tooze; Rachel Geller; Bayard L Powell; Timothy S Pardee; Ellen Ritchie; LeAnne Kennedy; Kathryn E Callahan; Heidi D Klepin
Journal:  Leuk Res       Date:  2014-07-07       Impact factor: 3.156

Review 7.  Managing multiple myeloma in elderly patients.

Authors:  Evan Diamond; Oscar B Lahoud; Heather Landau
Journal:  Leuk Lymphoma       Date:  2017-08-28

8.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

Review 9.  Studies to reduce unnecessary medication use in frail older adults: a systematic review.

Authors:  Jennifer Tjia; Sarah J Velten; Carole Parsons; Sruthi Valluri; Becky A Briesacher
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

10.  Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.

Authors:  Jun Woo Park; Jong-Lyel Roh; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.